Rising Stars Shine: Multiple Innovative Biopharma Tenants of Simbay Park Named to 2024 GEI China Potential Unicorn List

Xingyiang (Shanghai) Biotechnology Co., Ltd. is an innovative biopharmaceutical company focused on developing next-generation immune cell products based on iPSC-derived CAR-NK technology for universal, mass-producible treatments targeting solid tumors and autoimmune diseases. The universal off-the-shelf immune cell therapy technology represents a popular area of research and innovation in the field of cellular drugs.

While independently developing innovations, the company actively collaborates with advanced institutions globally, focusing on developing universal off-the-shelf, mass-producible immune cell innovative drugs that target solid tumors and demonstrate clinical value. This significantly reduces the production cost of cellular products, providing safe and effective therapeutic options for patients worldwide.

Juventas, established in June 2018, has grown into a leading innovator in China's cell therapy industry, aspiring to become a globally leading biopharmaceutical enterprise driven by cutting-edge cell and gene technologies. The company’s first core product, Yuanruida® (Nabriocin Injection, CNCT19), was officially approved for marketing by the National Medical Products Administration in November 2023. This product is the first CAR-T drug in the field of leukemia treatment in China and also the first fully self-innovated CD19 CAR-T drug in China.

The company has deeply cooperated with top national institutions in China to build an international new drug research and development system centered on technology platforms such as CAR, iPSCs, and gene editing. It has more than 10 pipeline products under research and development, covering diseases in the fields of hematological tumors, solid tumors, and autoimmune diseases.

HuiGene is a global clinical-stage biotechnology company focused on designing, engineering, and developing novel CRISPR gene-editing tools and disruptive innovative gene therapies. Headquartered in Shanghai, China, with an office in New Jersey, USA, HuiGene aims to leverage gene-editing technology to address the pressing needs of patients worldwide, with a research pipeline covering ophthalmology, central nervous system, and other fields.

Huigene's CRISPR-based gene therapy has the potential to cure life-threatening diseases by fundamentally repairing genes, transforming the future of gene-editing medicine.

VelaVigo was founded in October 2021 by seasoned industry scientists and is a new drug research and development enterprise based in China with a global outlook.

The company is committed to disease biology as its foundation and drug discovery as its innovative engine, focusing on new technologies related to large molecules, including bispecific/multi-specific antibodies, ADCs, and novel molecular types. It aims to establish a comprehensive system that fully covers the value chain of innovative drugs, including the construction of new drug discovery technology platforms, CMC development, translational science, clinical development, and complete capabilities for commercialization. Dedicated to research and innovation, the company persists in the long-term and all-around development of effective innovative drugs needed by patients, providing affordable, differentiated high-quality biologics to meet unmet clinical needs of patients worldwide.

In the new field of epigenetic gene therapy, there are only four or five biotechnology companies globally so far. EpiLogic, established in the second half of 2021, represents China in making its voice heard in this cutting-edge international scientific domain.

Currently, Juventas has developed epigenetic regulation tools that can precisely and efficiently regulate the expression of pathogenic target genes without altering the DNA sequence, offering a potential solution to the safety issues that have long troubled traditional gene editing. Based on the combination of "epigenetic regulators + precise delivery systems," the Juventas team has established R&D pipelines in the fields of metabolic cardiovascular diseases, chronic hepatitis B, ophthalmology, neurodegenerative diseases, and rare diseases. The first product under research is about to enter the human trial stage.